Sign in

You're signed outSign in or to get full access.

Jana

Research Analyst at TD Cowen

Jana Zinn is Managing Director and Head of Corporate Access & Advisory at TD Cowen, specializing in capital markets and corporate advisory services. She works closely with companies in the AI, technology, and capital markets sectors, providing strategic access and insights, though specific performance metrics or company coverage are not publicly reported. Jana has led corporate access and advisory initiatives since joining TD Cowen, and her previous experience includes significant work in related fields, though earlier employers and exact career dates are undisclosed. Her role as Managing Director implies advanced professional credentials and regulatory compliance, although specific securities licenses or FINRA registrations are not confirmed in public sources.

Jana's questions to Legend Biotech (LEGN) leadership

Question · Q3 2025

Jana, on behalf of Clara Dong, requested comments on Legend Biotech's strong international growth, identifying areas of strongest demand and higher growth potential after the TechLane facility comes online, and how TechLane's capacity will impact E.U. market share in 2026 and beyond.

Answer

Alan Bash, President of CARVYKTI, highlighted strong international uptake in Germany, Spain, and Belgium, noting that European markets value CARVYKTI's one-time infusion, durability, and PFS/OS benefits, supporting earlier use. He confirmed that TechLane is now commercially online and, combined with Ovalt, will meet the capacity demands for growing European launches.

Ask follow-up questions

Fintool

Fintool can predict Legend Biotech logo LEGN's earnings beat/miss a week before the call